ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.

WACC (Weighted Average Cost of Capital): 11.05%, coming from 11.5% cost of equity (about 11% I use for a no-moat stock, but I ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025ORX750 Phase 2a ...

There are many different types of sleep disorders, which can lead to additional symptoms and issues like increased depression ...

Avantax Advisory Services Inc. acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 2,140 ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) will likely be announcing its earnings results before the market opens on ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") ...

Harmony Biosciences Holdings, Inc. , today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, ...

Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical ...

Centessa Pharmaceuticals PLC (NASDAQ: CNTA) recently reported its business highlights and financial results for the fourth ...

While reading for just six minutes reduced stress by 68%, listening to music prompted a 61% reduction, drinking tea or coffee ...